67
Participants
Start Date
November 17, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
February 29, 2028
Carboplatin + Paclitaxel + Durvalumab
Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
Caen - CHU Côte de Nacre, Caen
CHU Toulouse, Toulouse
CHU Montpellier, Montpellier
Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg
Abbeville - CH, Abbeville
Amiens - Clinique de l'Europe, Amiens
Angers - CHU, Angers
Besançon - CHU, Besançon
Bordeaux - CHU, Bordeaux
Boulogne - Ambroise Paré, Boulogne-Billancourt
Chambéry - CH, Chambéry
Cholet - CH, Cholet
Colmar - CH, Colmar
Annemasse - CH, Contamine-sur-Arve
Créteil - CHI, Créteil
Dijon - CHU Bocage, Dijon
Grenoble - CHU, Grenoble
Le Mans - CHG, Le Mans
Lyon - URCOT, Lyon
Marseille - APHM, Marseille
Marseille - Hôpital Européen, Marseille
Morlaix - CH, Morlaix
Orléans - CHR, Orléans
Paris - Bichat, Paris
Paris - Hôpital Cochin, Paris
Paris - Tenon, Paris
Rennes - CHU, Rennes
Toulon - Sainte Anne HIA, Toulon
Tours - CHU, Tours
Vandoeuvre-lès-Nancy - CRLCC, Vandœuvre-lès-Nancy
Villefranche sur Saône - CH, Villefranche-sur-Saône
Intergroupe Francophone de Cancerologie Thoracique
OTHER